- Home
- UUUU vs PRAX Comparison
UUUU vs PRAX Comparison
Compare UUUU & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UUUU | PRAX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 8.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | UUUU | PRAX |
|---|---|---|
| Price | $24.60 | $303.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $17.00 | ★ $397.85 |
| AVG Volume (30 Days) | ★ 13.2M | 596.9K |
| Earning Date | 02-25-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $78,742,000.00 | $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $174.53 | $14,827.76 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 103.69 | ★ 364.98 |
| 52 Week Low | $3.20 | $26.70 |
| 52 Week High | $27.33 | $326.91 |
Technical Indicators
Market Signals| Indicator | UUUU | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 75.46 | 59.12 |
| Support Level | $20.88 | $266.93 |
| Resistance Level | $24.35 | $326.83 |
| Average True Range (ATR) | 1.94 | 18.50 |
| MACD | 0.65 | -0.64 |
| Stochastic Oscillator | 96.35 | 61.54 |
Price Performance
Historical ComparisonAbout UUUU Energy Fuels Inc (Canada)
Energy Fuels Inc is a United States-based critical minerals company. The Company mines uranium and produces natural uranium concentrates that are sold to nuclear utilities for the production of carbon-free nuclear energy. It holds two of America's key uranium production centers: The White Mesa Mill in Utah, and the Nichols Ranch ISR Facility in Wyoming. It has three reportable segments based on its operations and financial information; Uranium, HMS, and REE.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.